Related content

A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors

By Yan Zhao   Zhu Zhongling   Li Kai   Chen Peng   Wang Liuchun   Huang Chun   Xue Jinhuai   Liu Meijun  

Cancer Chemotherapy and Pharmacology, Vol. 67, Iss. 4, 2011-04 ,pp. : 955-961

Springer Publishing Company

Access to resources Recommend Favorite

A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

By Chow Laura   Eckhardt S.   O’Bryant Cindy   Schultz Mary   Morrow Mark   Grolnic Stacy   Basche Michele   Gore Lia  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 4, 2008-09 ,pp. : 631-646

Springer Publishing Company

Access to resources Recommend Favorite

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

By Murakami H.   Kurata T.   Onozawa Y.   Watanabe J.   Ono A.   Takahashi T.   Yamamoto N.   Fujisaka Y.   Kiyota H.   Hayashi H.   Tanaka K.   Nakagawa K.   Kuroda S.  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 623-630

Springer Publishing Company

Access to resources Recommend Favorite

A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors

By Plummer Ruth   Madi Ayman   Jeffels Melinda   Richly Heike   Nokay Bahar   Rubin Stephen   Ball Howard   Weller Steve   Botbyl Jeffrey   Gibson Diana   Scheulen Max  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 93-101

Springer Publishing Company

Access to resources Recommend Favorite

Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors

By  

The Oncologist, Vol. 23, Iss. 2, 2018-02 ,pp. : 155-e17

John Wiley & Sons Inc

Access to resources Recommend Favorite